TransMedics Group, Inc. $TMDX Shares Purchased by Bessemer Group Inc.

Bessemer Group Inc. grew its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 38.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,821 shares of the company’s stock after purchasing an additional 12,812 shares during the period. Bessemer Group Inc.’s holdings in TransMedics Group were worth $4,555,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in TMDX. Royal Bank of Canada raised its position in TransMedics Group by 47.9% in the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after purchasing an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of TransMedics Group by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after buying an additional 868 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the period. Russell Investments Group Ltd. grew its stake in shares of TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after buying an additional 938 shares in the last quarter. Finally, M&T Bank Corp acquired a new stake in shares of TransMedics Group in the second quarter valued at about $209,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on TMDX shares. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. Needham & Company LLC lowered their price objective on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Stifel Nicolaus lifted their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, June 18th. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, TD Cowen reissued a “buy” rating and set a $120.00 target price on shares of TransMedics Group in a research report on Wednesday, July 1st. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $134.50.

Insiders Place Their Bets

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

TransMedics Group Stock Performance

TransMedics Group stock opened at $73.47 on Tuesday. The stock has a market cap of $2.54 billion, a P/E ratio of 16.70 and a beta of 1.89. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The stock has a 50 day moving average of $71.02 and a 200-day moving average of $104.11. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.70 EPS. On average, analysts expect that TransMedics Group, Inc. will post 1.92 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.